PA
TVTX icon

Parallel Advisors’s Travere Therapeutics TVTX Stock Holding History

Parallel Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.4K Sell
2,707
-1,078
-28% -$32.2K ﹤0.01% 1715
2025
Q4 		$145K Buy
3,785
+3,003
+384% +$97.6K ﹤0.01% 1256
2025
Q3 		$18.7K Buy
782
+400
+105% +$7.52K ﹤0.01% 2280
2025
Q2 		$5.65K Hold
382
– – ﹤0.01% 2697
2025
Q1 		$6.84K Hold
382
– – ﹤0.01% 2575
2024
Q4 		$6.65K Hold
382
– – ﹤0.01% 2536
2024
Q3 		$5.34K Hold
382
– – ﹤0.01% 2586
2024
Q2 		$3.14K Buy
382
+95
+33% +$640 ﹤0.01% 2670
2024
Q1 		$2.21K Hold
287
– – ﹤0.01% 2799
2023
Q4 		$2.58K Buy
+287
New +$2.09K ﹤0.01% 2725
2022
Q4 		– Sell
-41
Closed -$1K – 3524
2022
Q3 		$1K Buy
41
+37
+925% +$956 ﹤0.01% 3030
2022
Q2 		$0 Buy
+4
New +$101 ﹤0.01% 3367
2020
Q4 		– Sell
-94
Closed -$2K – 2725
2020
Q3 		$2K Hold
94
– – ﹤0.01% 2352
2020
Q2 		$1K Buy
+94
New +$1.5K ﹤0.01% 2377
2017
Q3 		– Sell
-10
Closed – – 2215
2017
Q2 		$0 Buy
+10
New +$181 ﹤0.01% 2211

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallel Advisors's TVTX Position: Q1 2026 in Review

Parallel Advisors reduced its Travere Therapeutics (TVTX) stake by 28% in Q1 2026, selling an estimated $32.2K and leaving 2,707 shares worth $80.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1715.

Parallel Advisors first reported a position in TVTX in Q2 2017 and has held it in 15 quarters since. The position peaked at $145K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Parallel Advisors held 2,707 shares of Travere Therapeutics worth $80.4K as of Q1 2026.
  • Parallel Advisors sold 1,078 Travere Therapeutics shares in Q1 2026, an estimated $32.2K.
  • Travere Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #1715 holding.
  • Parallel Advisors first reported a position in Travere Therapeutics in Q2 2017 and has held it in 15 quarters since.
  • Parallel Advisors's Travere Therapeutics position peaked at $145K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.